Figure 2.
Prevalence of elevated fraction of exhaled nitric oxide (FeNO; ≥25 parts per billion) in all people living with human immunodeficiency virus (PLWH) and uninfected controls (A) and restricted to those with asthma (B), allergy (C), or reported current smoking (D). *P value for the difference between PLWH and uninfected controls < .05.

Prevalence of elevated fraction of exhaled nitric oxide (FeNO; ≥25 parts per billion) in all people living with human immunodeficiency virus (PLWH) and uninfected controls (A) and restricted to those with asthma (B), allergy (C), or reported current smoking (D). *P value for the difference between PLWH and uninfected controls < .05.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close